AbbVie said on Friday that the U.S. Food and Drug Administration approved its drug for complicated intra-abdominal infections ...

Drugmaker Pfizer posted a better-than-expected fourth-quarter profit on Thursday, helped by cost cuts it began last year as ...

Pfizer has ended development of a B7-H4-directed antibody-drug conjugate (ADC), triggering a $1 billion impairment charge. | ...

Investors looking for ways to pump up their passive income streams might want to turn their heads toward the pharmaceutical ...

The results could sway U.S. regulators to convert Braftovi’s accelerated clearance in colorectal tumors into a full approval ...

The pharmaceutical giant named Jeffrey Legos the head of a division it is counting on to overcome investor pressure and grow ...

Pfizer and Merck, ostensibly beleaguered drugmakers, have seen their shares battered despite reporting strong earnings.

(Reuters) -Drugmaker Pfizer beat Wall Street estimates for fourth-quarter profit on Thursday, boosted by cost-cutting, a ...

Less than two months after an accelerated approval from the FDA, a drug combination featuring Pfizer’s Braftovi has turned in ...

A Pfizer drug recently awarded accelerated FDA approval in colorectal cancer now has additional data showing it met key goals in its pivotal study, results that could support an application ...

In mid-2024, the commercial president of Pfizer’s oncology unit Suneet Varma announced his retirement after 15 years with the ...

Pfizer's Q4 2024 earnings beat expectations, but concerns over 2025 guidance and patent expirations led to stock decline. See ...